Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 9/20 | 0.48 |
| ▸ | HTR2C | P28335 | 8/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | FAM20C | Q8IXL6 | 1/20 | 0.46 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.46 |
| ▸ | APOBEC3A | P31941 | 4/20 | 0.45 |
| ▸ | APOBEC3G | Q9HC16 | 4/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CDK4 | P11802 | 1/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14020277 | 1.00 | BRD4 (0.50) | BRD4HTR2AHTR2CL3MBTL1ALDH1A1 | |
| SCHEMBL4876612 | 0.91 | HTR2A (0.51) | HTR2AHTR2CL3MBTL1ALDH1A1GAA | |
| SCHEMBL4621383 | 0.89 | HTR2A (0.49) | HTR2AHTR2CL3MBTL1APOBEC3AAPOBEC3G | |
| SCHEMBL4624192 | 0.88 | HTR2A (0.51) | BRD4HTR2AHTR2CL3MBTL1APOBEC3A | |
| SCHEMBL4877632 | 0.87 | HTR2A (0.51) | HTR2AHTR2CL3MBTL1ALDH1A1GAA | |
| SCHEMBL3306451 | 0.87 | HTR2A (0.64) | HTR2AHTR2CL3MBTL1ALDH1A1GAA | |
| SCHEMBL4623988 | 0.84 | HTR2A (0.59) | HTR2AHTR2CL3MBTL1ALDH1A1GAA | |
| SCHEMBL14020100 | 0.82 | CDK2 (0.44) | HTR2AHTR2CL3MBTL1APOBEC3AAPOBEC3G | |
| SCHEMBL4623472 | 0.82 | HTR2A (0.55) | HTR2AHTR2CL3MBTL1ALDH1A1GAA | |
| SCHEMBL4880639 | 0.81 | CDK4 (0.42) | BRD4HTR2AHTR2CL3MBTL1APOBEC3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080269170-A1 | Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors | SANOFI-AVENTIS (FR) | 2008-10-30 | — | — | US | disclosed |
| EP-1904479-A2 | NOVEL 2,4-DIANILINOPYRIMIDINE DERIVATIVES, THE PREPARATION THEREOF, THEIR USE AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND, IN PARTICULAR, AS IKK INHIBITORS | Sanofi-Aventis (FR) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007006926-A2 | NOVEL 2,4-DIANILINOPYRIMIDINE DERIVATIVES, THE PREPARATION THEREOF, THEIR USE AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND, IN PARTICULAR, AS IKK INHIBITORS | SANOFI-AVENTIS (FR) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080269170-A1 | Novel 2,4-Dianilinopyrimidine Derivatives, the Preparation Thereof, Their Use as Medicaments, Pharmaceutical Compositions and, in Particular, as IKK Inhibitors | NFKBIA, IKBKB, IKBKE | BRD4 1183/4885HTR2A 3453/4885HTR2C 3934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.